Altre lingue Cassava Sciences, Inc.

Azioni

SAVA

US14817C1071

Tempo reale stimato Cboe BZX Altri mercati azionari 20:11:52 01/05/2024			Variaz. 5gg	Var. 1 gen.
22,09 ^USD	-0,27%		+6,51%	-1,87%

25/03	Cassava Sciences annuncia il completamento della revisione intermedia della sicurezza del candidato farmaco per l'Alzheimer Simufilam	MT
25/03	Cassava Sciences, Inc. annuncia il completamento di una revisione intermedia della sicurezza di Simufilam orale negli studi di Fase 3 in corso	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	15:10
North American Morning Briefing : Investors Brace -2-	29/04
Cassava Sciences : Corporate Presentation – Second Quarter 2024	24/04
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	16/04
Redemption Date Announced for Warrants	15/04
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	29/03
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	27/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	27/03
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25/03
Cassava Sciences : Corporate Presentation – First Quarter 2024	25/03
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	25/03
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25/03
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	21/03
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	20/03
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	19/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	19/03
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	17/03
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA	15/03
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	13/03
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?	13/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cassava Sciences, Inc.

Azioni

SAVA

US14817C1071

Altre lingue

Filtri